Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers

NCT01190878 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

169

Enrollment

INDUSTRY

Sponsor class

Conditions

Ocular Inflammation

Interventions

DRUG: ISV-303
DRUG: ISV-303
DRUG: DuraSite Vehicle
DRUG: Xibrom™

Sponsor

Sun Pharmaceutical Industries Limited